Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 158

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Fecal transplantation for treatment of inflammatory bowel disease

Open access
Imdad, Aamer, Nicholson, Maribeth R, Tanner-Smith, Emily E, Zackular, Joseph P, Gomez-Duarte, Oscar, Borromeo Beaulieu, Dawn M, Acra, Sari · 2017 · Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: Inflammatory bowel disease (IBD) is a chronic, relapsing disease of the gastrointestinal tract that is thought to be associated with a complex interplay between microbes and the immune system, leading to an abnormal inflammatory response in genetically susceptible individuals. Dysbiosis, characterized by the alteration of the composition of the resident commensal bacteria in a host compared to healthy individuals, is thought to play a major role in the pathogenesis of ulcerative colitis (UC) and Crohn's disease (CD), two subtypes of IBD. There is growing interest to correct the underlying dysbiosis through the use of fecal microbiota transplantation (FMT) for the treatment of IBD. OBJECTIVES: The objective of this systematic review was to assess the efficacy and safety of FMT for the treatment of IBD. SEARCH METHODS: We searched the MEDLINE, Embase, Cochrane Library, and Cochrane IBD Group Specialized Register databases from inception to 19 March 2018. We also searched ClinicalTrials.gov, ISRCTN metaRegister of Controlled Trials, and the Conference Proceedings Citation Index. SELECTION CRITERIA: Only randomized trials or non-randomized studies with a control arm were considered for inclusion. Adults or pediatric participants with UC or CD were eligible for inclusion. Eligible interventions were FMT defined as the administration of fecal material containing distal gut microbiota from a healthy donor to the gastrointestinal tract of a someone with UC or CD. The comparison group included participants who did not receive FMT and were given placebo, autologous FMT, or no intervention. DATA COLLECTION AND ANALYSIS: Two authors independently screened the titles and extracted data from the included studies. We used the Cochrane risk of bias tool to assess study bias. The primary outcomes were induction of clinical remission, clinical relapse, and serious adverse events. Secondary outcomes included clinical response, endoscopic remission and endoscopic response, quality of life scores, laboratory measures of inflammation, withdrawals, and microbiome outcomes. We calculated the risk ratio (RR) and corresponding 95% confidence interval (95% CI) for dichotomous outcomes and the mean difference and 95% CI for continuous outcomes. Random-effects meta-analysis models were used to synthesize effect sizes across trials. The overall certainty of the evidence supporting the primary and selected secondary outcomes was rated using the GRADE criteria. MAIN RESULTS: Four studies with a total of 277 participants were included. These studies assessed the efficacy of FMT for treatment of UC in adults; no eligible trials were found for the treatment of CD. Most participants had mild to moderate UC. Two studies were conducted in Australia, one study was conducted in Canada, and another in the Netherlands. Three of the included studies administered FMT via the rectal route and one study administered FMT via the nasoduodenal route. Three studies were rated as low risk of bias. One study (abstract publication) was rated as unclear risk of bias. Combined results from four studies (277 participants) suggest that FMT increases rates of clinical remission by two-fold in patients with UC compared to controls. At 8 weeks, 37% (52/140) of FMT participants achieved remission compared to 18% (24/137) of control participants (RR 2.03, 95 % CI, 1.07 to 3.86; I² = 50%; low certainty evidence). One study reported data on relapse at 12 weeks among participants who achieved remission. None of the FMT participants (0/7) relapsed at 12 weeks compared to 20% of control participants (RR 0.28, 95% CI 0.02 to 4.98, 17 participants, very low certainty evidence). It is unclear whether there is a difference in serious adverse event rates between the intervention and control groups. Seven per cent (10/140) of FMT participants had a serious adverse event compared to 5% (7/137) of control participants (RR 1.40, 95% CI 0.55 to 3.58; 4 studies; I² = 0%; low certainty evidence). Serious adverse events included worsening of UC necessitating intravenous steroids or surgery; infection such as Clostridium difficile and cytomegalovirus, small bowel perforation and pneumonia. Adverse events were reported by two studies and the pooled data did not show any difference between the study groups. Seventy-eight per cent (50/64) of FMT participants had an adverse event compared to 75% (49/65) of control participants (RR 1.03, 95% CI 0.81 to 1.31; I² = 31%; moderate certainty evidence). Common adverse events included abdominal pain, nausea, flatulence, bloating, upper respiratory tract infection, headaches, dizziness, and fever. Four studies reported on clinical response at 8 weeks. Forty-nine per cent (68/140) of FMT participants had a clinical response compared to 28% (38/137) of control participants (RR 1.70, 95% CI 0.98 to 2.95, I² = 50%, low certainty evidence). Endoscopic remission at 8 weeks was reported by three studies and the combined results favored FMT over

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd012774

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 37

  1. Abraham, 2012, Natural history of pediatric-onset inflammatory bowel disease: a systematic review, Journal of Clinical Gastroenterology, 46, 581, 10.1097/MCG.0b013e318247c32f · DOI · Paper page
  2. Ahuja, 2010, Inflammatory bowel disease in the Asia-Pacific area: a comparison with developed countries and regional differences, Journal of Digestive Diseases, 11, 134, 10.1111/j.1751-2980.2010.00429.x · DOI · Paper page
  3. Alang, 2015, Weight gain after fecal microbiota transplantation, Open Forum Infectious Diseases, 2, ofv004, 10.1093/ofid/ofv004 · DOI · Paper page
  4. Assa, 2016, Mucosa-Associated Ileal Microbiota in New-Onset Pediatric Crohn's Disease, Inflammatory Bowel Diseases, 22, 1533, 10.1097/MIB.0000000000000776 · DOI
  5. Austin, 2014, Fecal microbiota transplantation in the treatment of Clostridium difficile infections, American Journal of Medicine, 127, 479, 10.1016/j.amjmed.2014.02.017 · DOI
  6. Bejaoui, 2015, Targeting the Microbiome in Inflammatory Bowel Disease: Critical Evaluation of Current Concepts and Moving to New Horizons, Digestive Diseases, 33 Suppl 1, 105, 10.1159/000437104 · DOI
  7. Cammarota, 2015, Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection, Alimentary Pharmacology & Therapeutics, 41, 835, 10.1111/apt.13144 · DOI · Paper page
  8. Cleynen I Boucher G Jostins L Schumm LP Zeissig S Ahmad T Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study Lancet 2016 156 67 · DOI · Paper page
  9. Dahlhamer, 2016, Prevalence of Inflammatory Bowel Disease Among Adults Aged ≥ 18 Years - United States, 2015, MMWR. Morbidity and Mortality Weekly Report, 65, 1166, 10.15585/mmwr.mm6542a3 · DOI · Paper page
  10. Preter, 2012, Decreased mucosal sulfide detoxification is related to an impaired butyrate oxidation in ulcerative colitis, Inflammatory Bowel Diseases, 18, 2371, 10.1002/ibd.22949 · DOI · Paper page
  11. Feakins, 2013, Inflammatory bowel disease biopsies: updated British Society of Gastroenterology reporting guidelines, Journal of Clinical Pathology, 66, 1005, 10.1136/jclinpath-2013-201885 · DOI · Paper page
  12. Fuentes, 2017, Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota transplantation, ISME Journal, 11, 1877, 10.1038/ismej.2017.44 · DOI · Paper page
  13. Kelly, 2014, Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients, American Journal of Gastroenterology, 109, 1065, 10.1038/ajg.2014.133 · DOI · Paper page
  14. Kelly CR Khoruts A Staley C Sadowsky MJ Abd M Alani M Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial Annals of Internal Medicine 2016 609 16 · DOI · Paper page
  15. Khoruts, 2016, Inflammatory Bowel Disease Affects the Outcome of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection, Clinical Gastroenterology & Hepatology, 14, 1433, 10.1016/j.cgh.2016.02.018 · DOI · Paper page
  16. Kostic, 2014, The microbiome in inflammatory bowel disease: current status and the future ahead, Gastroenterology, 146, 1489, 10.1053/j.gastro.2014.02.009 · DOI · Paper page
  17. Leffler, 2015, Clostridium difficile infection, New England Journal of Medicine, 372, 1539, 10.1056/NEJMra1403772 · DOI · Paper page
  18. Link, 2016, Endoscopic peroral jejunal fecal microbiota transplantation, Digestive & Liver Disease, 48, 1336, 10.1016/j.dld.2016.08.110 · DOI
  19. Mallon, 2007, Probiotics for induction of remission in ulcerative colitis, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005573.pub2 · DOI · Paper page
  20. Mehta, 2016, Report: economic implications of inflammatory bowel disease and its management, American Journal of Managed Care, 22, s51
  21. Molodecky, 2012, Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review, Gastroenterology, 142, 46, 10.1053/j.gastro.2011.10.001 · DOI · Paper page
  22. Morgan, 2012, Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment, Genome Biology, 13, R79, 10.1186/gb-2012-13-9-r79 · DOI · Paper page
  23. Mowat C Cole A Windsor A Ahmad T Arnott I Driscoll R Guidelines for the management of inflammatory bowel disease in adults Gut 2011 571 607 · DOI · Paper page
  24. Nagao-Kitamoto, 2016, Functional Characterization of Inflammatory Bowel Disease-Associated Gut Dysbiosis in Gnotobiotic Mice, Cellular and Molecular Gastroenterology and Hepatology, 2, 468, 10.1016/j.jcmgh.2016.02.003 · DOI · Paper page
  25. Naidoo, 2011, Probiotics for maintenance of remission in ulcerative colitis, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD007443.pub2 · DOI
  26. Osman, 2016, Donor Efficacy in Fecal Microbiota Transplantation for Recurrent Clostridium difficile: Evidence From a 1,999-Patient Cohort, Open Forum Infectious Diseases, 3, 841, 10.1093/ofid/ofw194.48 · DOI
  27. Owens, 2013, Fecal microbiota transplantation and donor standardization, Trends in Microbiology, 21, 443, 10.1016/j.tim.2013.07.003 · DOI
  28. Petersen, 2014, Defining dysbiosis and its influence on host immunity and disease, Cellular Microbiology, 16, 1024, 10.1111/cmi.12308 · DOI · Paper page
  29. Rapozo, 2017, Diet and microbiota in inflammatory bowel disease: The gut in disharmony, World Journal of Gastroenterology, 23, 2124, 10.3748/wjg.v23.i12.2124 · DOI · Paper page
  30. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014
  31. Schulberg, 2016, Characterisation and therapeutic manipulation of the gut microbiome in inflammatory bowel disease, Internal Medicine Journal, 46, 266, 10.1111/imj.13003 · DOI
  32. Shi, 2016, Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis, PLoS One, 11, e0157259, 10.1371/journal.pone.0157259 · DOI
  33. Singh, 2015, Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD001176.pub3 · DOI · Paper page
  34. Solari, 2014, Tempered enthusiasm for fecal transplant, Clinical Infectious Diseases, 59, 319, 10.1093/cid/ciu278 · DOI
  35. Sun, 2016, Fecal Microbiota Transplantation as a Novel Therapy for Ulcerative Colitis: A Systematic Review and Meta-Analysis, Medicine, 95, e3765, 10.1097/MD.0000000000003765 · DOI
  36. Vindigni, 2016, The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions, Therapeutic Advances in Gastroenterology, 9, 606, 10.1177/1756283X16644242 · DOI · Paper page
  37. Weintraub, 2014, Temporal trends in inflammatory bowel disease publications over a 19-years period, World Journal of Gastroenterology, 20, 16745, 10.3748/wjg.v20.i44.16745 · doi:10.3748/wjg.v20.i44.16745

Cited by

See all 158

Metadata

Authors
Imdad, A., Nicholson, M. R., Tanner-Smith, E. E., Zackular, J. P., Gomez-Duarte, O., Borromeo Beaulieu, D. M., & Acra, S.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2017-08-23
Volume
11
Pages
CD012774-CD012774
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W2745821596
Cited by
158
References
21
FWCI
10.47
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fecal transplantation for treatment of inflammatory bowel disease. https://app.cochat.ai/papers/10.1002/14651858.cd012774
The paper
Imdad, A., Nicholson, M. R., Tanner-Smith, E. E., Zackular, J. P., Gomez-Duarte, O., Borromeo Beaulieu, D. M., & Acra, S. (2017). Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd012774

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.